Top-Selling Drugs in India
Author:
Intellectual Market Insights Research
Published Date:
01 Jun 2026
Executive Summary of Top-Selling Drugs in India
India represents the world's third-largest pharmaceutical market by volume and is valued at approximately ?2.1-2.3 lakh crore (USD 25-27 billion) as of 2024-2025. The market is experiencing robust growth at a CAGR of 8-10% and is projected to reach USD 130 billion by 2030. Unlike Western markets dominated by patented biologics, India's pharmaceutical sector is characterized by branded generics and a significant shift from acute to chronic disease management, reflecting changing demographics and lifestyle patterns.
Top Therapeutic Segments by Market Share
The Indian pharmaceutical market is strategically segmented across key therapeutic areas, with chronic disease management increasingly dominating sales:
|
Rank |
Therapeutic Category |
Market Share |
Key Market Drivers |
|
1 |
Anti-Infectives |
13-15% |
High infection burden, respiratory infections, TB |
|
2 |
Cardiovascular |
12-14% |
Rising CVD cases, hypertension epidemic |
|
3 |
Gastro-Intestinal |
11-13% |
Lifestyle-related digestive disorders, acidity |
|
4 |
Anti-Diabetics |
10-12% |
India's diabetes epidemic (77 million diabetics) |
|
5 |
Vitamins & Nutrients |
9-11% |
Nutritional deficiencies, wellness awareness |
|
6 |
Respiratory |
7-9% |
Air pollution, asthma, COPD prevalence |
|
7 |
Pain Management |
7-8% |
Musculoskeletal disorders, fever management |
|
8 |
Dermatology |
5-7% |
Skin infections, allergic conditions |
Top-Selling Drug Molecules and Leading Brands
- Pantoprazole (Proton Pump Inhibitor)
- Market Size: ?3,500-4,000+ crore annually
- Primary Use: Acid reflux, GERD, peptic ulcers
- Leading Brands:
- Pantocid (Sun Pharma) - Market leader
- Pan-D (Alkem Laboratories) - Combination with Domperidone
- Nexpro (Torrent Pharma)
- Pantodac (Zydus Cadila)
- Atorvastatin (Statin for Cardiovascular Health)
- Market Size: ?2,500-3,000+ crore annually
- Primary Use: High cholesterol, cardiovascular disease prevention
- Leading Brands:
- Atorva (Zydus Cadila)
- Tonact (Lupin)
- Lipicure (IPCA Laboratories)
- Storvas (Sun Pharma)
- Amoxicillin + Clavulanic Acid (Broad-Spectrum Antibiotic)
- Market Size: ?2,000-2,500+ crore annually
- Primary Use: Bacterial infections (respiratory, urinary, skin)
- Leading Brands:
- Augmentin (GSK India) - Consistent market leader by revenue
- Clavam (Alkem Laboratories)
- Moxikind-CV (Mankind Pharma)
- Advent (Sun Pharma)
- Metformin (Anti-Diabetic)
- Market Size: ?2,000-2,500+ crore annually
- Primary Use: Type 2 diabetes management
- Leading Brands:
- Glycomet (USV Pharma) - Including combination formulations
- Glucophage (Abbott India)
- Obimet (Glenmark)
- Levothyroxine (Thyroid Hormone)
- Market Size: ?1,200-1,500+ crore annually
- Primary Use: Hypothyroidism treatment
- Leading Brands:
- Thyronorm (Abbott India) - Dominant market leader with ~70% market share
- Human Insulin (Diabetes Management)
- Market Size: ?1,800-2,200+ crore annually
- Primary Use: Type 1 and Type 2 diabetes
- Leading Brands:
- Mixtard (Novo Nordisk) - Biphasic insulin
- Lantus (Sanofi) - Long-acting insulin glargine
Leading Pharmaceutical Companies by Market Share
|
Rank |
Company |
Market Share |
Key Therapeutic Strengths |
|
1 |
Abbott India |
7-8% |
Thyronorm, women's health, nutrition |
|
2 |
Sun Pharmaceutical |
7-8% |
Dermatology, cardiology, neurology |
|
3 |
Cipla |
5-6% |
Respiratory care, anti-infectives |
|
4 |
Mankind Pharma |
5-6% |
Mass-market brands, OTC products |
|
5 |
Alkem Laboratories |
4-5% |
Anti-infectives, gastroenterology |
High-Growth Market Trends and Emerging Categories
- GLP-1 Agonists for Diabetes/Obesity: Growing at 28% CAGR as awareness of newer diabetes treatments increases
- Oncology Therapeutics: Expanding at 17% CAGR driven by improved diagnosis and treatment access
- Mental Health Medications: Post-COVID awareness driving 13% growth in antidepressants and anxiolytics
- Respiratory Biologics: Advanced asthma and COPD treatments seeing rapid urban adoption
- Nutraceuticals and Wellness Products: Double-digit growth driven by preventive healthcare awareness
Key Market Insights
- Dolo 650 (Paracetamol) sold over 350 crore tablets in a single month during COVID-19 peak
- India operates 600+ US-FDA approved manufacturing facilities - the highest outside the USA
- Chronic therapy prescriptions now account for over 55% of total prescription sales, overtaking acute care
- The top 300 pharmaceutical brands represent approximately 40-45% of total market value
- India exports medicines to over 200 countries, cementing its position as the "Pharmacy of the World"
